200 related articles for article (PubMed ID: 26972640)
21. Whole-pelvis radiotherapy in combination with interstitial brachytherapy: does coverage of the pelvic lymph nodes improve treatment outcome in high-risk prostate cancer?
Bittner N; Merrick GS; Wallner KE; Butler WM; Galbreath R; Adamovich E
Int J Radiat Oncol Biol Phys; 2010 Mar; 76(4):1078-84. PubMed ID: 19553031
[TBL] [Abstract][Full Text] [Related]
22. Initial management of prostate-specific antigen-detected, low-risk prostate cancer and the risk of death from prostate cancer.
Aizer AA; Chen MH; Hattangadi J; D'Amico AV
BJU Int; 2014 Jan; 113(1):43-50. PubMed ID: 23473327
[TBL] [Abstract][Full Text] [Related]
23. Predictors of mortality after androgen-deprivation therapy in patients with rapidly rising prostate-specific antigen levels after local therapy for prostate cancer.
Rodrigues NA; Chen MH; Catalona WJ; Roehl KA; Richie JP; D'Amico AV
Cancer; 2006 Aug; 107(3):514-20. PubMed ID: 16795068
[TBL] [Abstract][Full Text] [Related]
24. Improvement in prostate cancer survival over time: a 20-year analysis.
Kim MM; Hoffman KE; Levy LB; Frank SJ; Pugh TJ; Choi S; Nguyen QN; McGuire SE; Lee AK; Kuban DA
Cancer J; 2012; 18(1):1-8. PubMed ID: 22290249
[TBL] [Abstract][Full Text] [Related]
25. A competing risk analysis of cancer-specific mortality of initial treatment with radical prostatectomy versus radiation therapy in clinically localized high-risk prostate cancer.
Lee JY; Cho KS; Kwon JK; Jeh SU; Kang HW; Diaz RR; Ham WS; Koom WS; Keum KC; Choi YD
Ann Surg Oncol; 2014 Nov; 21(12):4026-33. PubMed ID: 24841351
[TBL] [Abstract][Full Text] [Related]
26. "Lumping" vs "splitting" in oncologic pathology: association with cancer center type and case volume.
Gansler T; Fedewa SA; Flanders D; Virgo KS; Ward EM
J Registry Manag; 2012; 39(2):43-52. PubMed ID: 23599028
[TBL] [Abstract][Full Text] [Related]
27. Statin use and risk of prostate cancer recurrence in men treated with radiation therapy.
Gutt R; Tonlaar N; Kunnavakkam R; Karrison T; Weichselbaum RR; Liauw SL
J Clin Oncol; 2010 Jun; 28(16):2653-9. PubMed ID: 20421534
[TBL] [Abstract][Full Text] [Related]
28. Lack of benefit of pelvic radiation in prostate cancer patients with a high risk of positive pelvic lymph nodes treated with high-dose radiation.
Vargas CE; Galalae R; Demanes J; Harsolia A; Meldolesi E; Nürnberg N; Schour L; Martinez A
Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1474-82. PubMed ID: 15964706
[TBL] [Abstract][Full Text] [Related]
29. Influence of the facility caseload on the subsequent survival of men with localized prostate cancer undergoing radical prostatectomy.
Barzi A; Lara PN; Tsao-Wei D; Yang D; Gill IS; Daneshmand S; Klein EA; Pinski JK; Penson DF; Quinn DI; Sadeghi S
Cancer; 2019 Nov; 125(21):3853-3863. PubMed ID: 31398279
[TBL] [Abstract][Full Text] [Related]
30. High-dose radiotherapy with or without androgen deprivation therapy for intermediate-risk prostate cancer: cancer control and toxicity outcomes.
Edelman S; Liauw SL; Rossi PJ; Cooper S; Jani AB
Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):1473-9. PubMed ID: 22245201
[TBL] [Abstract][Full Text] [Related]
31. Total androgen blockade versus a luteinizing hormone-releasing hormone agonist alone in men with high-risk prostate cancer treated with radiotherapy.
Nanda A; Chen MH; Moran BJ; Braccioforte MH; Dosoretz D; Salenius S; Katin M; Ross R; D'Amico AV
Int J Radiat Oncol Biol Phys; 2010 Apr; 76(5):1439-44. PubMed ID: 19540066
[TBL] [Abstract][Full Text] [Related]
32. Definition and Validation of "Favorable High-Risk Prostate Cancer": Implications for Personalizing Treatment of Radiation-Managed Patients.
Muralidhar V; Chen MH; Reznor G; Moran BJ; Braccioforte MH; Beard CJ; Feng FY; Hoffman KE; Choueiri TK; Martin NE; Sweeney CJ; Trinh QD; Nguyen PL
Int J Radiat Oncol Biol Phys; 2015 Nov; 93(4):828-35. PubMed ID: 26530751
[TBL] [Abstract][Full Text] [Related]
33. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
Kupelian P; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A; Kuban D
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):795-9. PubMed ID: 15925452
[TBL] [Abstract][Full Text] [Related]
34. Interval to biochemical failure predicts clinical outcomes in patients with high-risk prostate cancer treated by combined-modality radiation therapy.
Shilkrut M; McLaughlin PW; Merrick GS; Vainshtein JM; Feng FY; Hamstra DA
Int J Radiat Oncol Biol Phys; 2013 Jul; 86(4):721-8. PubMed ID: 23664325
[TBL] [Abstract][Full Text] [Related]
35. Association of androgen-deprivation therapy with excess cardiac-specific mortality in men with prostate cancer.
Ziehr DR; Chen MH; Zhang D; Braccioforte MH; Moran BJ; Mahal BA; Hyatt AS; Basaria SS; Beard CJ; Beckman JA; Choueiri TK; D'Amico AV; Hoffman KE; Hu JC; Martin NE; Sweeney CJ; Trinh QD; Nguyen PL
BJU Int; 2015 Sep; 116(3):358-65. PubMed ID: 25124891
[TBL] [Abstract][Full Text] [Related]
36. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
Martinez AA; Demanes DJ; Galalae R; Vargas C; Bertermann H; Rodriguez R; Gustafson G; Altieri G; Gonzalez J
Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1322-31. PubMed ID: 16029788
[TBL] [Abstract][Full Text] [Related]
37. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality.
Tsai HK; D'Amico AV; Sadetsky N; Chen MH; Carroll PR
J Natl Cancer Inst; 2007 Oct; 99(20):1516-24. PubMed ID: 17925537
[TBL] [Abstract][Full Text] [Related]
38. Is Treatment at a High-volume Center Associated with an Improved Survival for Primary Malignant Bone Tumors?
Malik AT; Alexander JH; Khan SN; Scharschmidt TJ
Clin Orthop Relat Res; 2020 Mar; 478(3):631-642. PubMed ID: 31714413
[TBL] [Abstract][Full Text] [Related]
39. Radical prostatectomy vs radiation therapy and androgen-suppression therapy in high-risk prostate cancer.
Westover K; Chen MH; Moul J; Robertson C; Polascik T; Dosoretz D; Katin M; Salenius S; D'Amico AV
BJU Int; 2012 Oct; 110(8):1116-21. PubMed ID: 22540922
[TBL] [Abstract][Full Text] [Related]
40. Causes of mortality after dose-escalated radiation therapy and androgen deprivation for high-risk prostate cancer.
Tendulkar RD; Hunter GK; Reddy CA; Stephans KL; Ciezki JP; Abdel-Wahab M; Stephenson AJ; Klein EA; Mahadevan A; Kupelian PA
Int J Radiat Oncol Biol Phys; 2013 Sep; 87(1):94-9. PubMed ID: 23920389
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]